Advanced glycation end products in nondiabetic patients with coronary artery disease.
about
Does accumulation of advanced glycation end products contribute to the aging phenotype?Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular DiseaseLow levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or realityMeta-analysis of RAGE gene polymorphism and coronary heart disease riskChemical modification of proteins by lipids in diabetes.Post-challenge hyperinsulinaemia rather than hyperglycaemia is associated with the severity of coronary artery disease in patients without a previous diagnosis of diabetes mellitusAdvanced glycation end products (AGEs) in relation to atherosclerotic lipid profiles in middle-aged and elderly diabetic patientsPostchallenge responses of nitrotyrosine and TNF-alpha during 75-g oral glucose tolerance test are associated with the presence of coronary artery diseases in patients with prediabetesPositive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography.Advanced glycation end-products in senile diabetic and non-diabetic patients with cardiovascular complicationsSkin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events.Association between carotid diameter and the advanced glycation end product N-epsilon-carboxymethyllysine (CML).Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications.Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy.Regulatory landscape of AGE-RAGE-oxidative stress axis and its modulation by PPARγ activation in high fructose diet-induced metabolic syndrome.Molecular basis of arterial stiffening: role of glycation - a mini-review.Review of the characteristics of food-derived and endogenous ne-carboxymethyllysine.Molecular effects of advanced glycation end products on cell signalling pathways, ageing and pathophysiology.Increasing physical activity: a step toward controlling metabolic syndrome.High serum advanced glycation end-products predict coronary artery disease irrespective of arterial stiffness in diabetic patientsThe relationship between glucose tolerance and severity of coronary artery disease using the Gensini score.Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study.Advanced glycation end products attenuate the function of tumor necrosis factor-like weak inducer of apoptosis to regulate the inflammatory response.Glycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging
P2860
Q24632710-520ED8C0-3AFD-4CB9-9B30-E122A13D259BQ26782422-AC0A7B91-BBCB-4255-B72B-F8C6CD6D0861Q26859793-9B59E287-CB46-4105-9D44-0A366CC52D67Q34510507-75F63C18-4B77-46F5-BC69-08CE93404FADQ35576075-E11EBCCA-ACE1-45D7-8476-5892B0592107Q35584209-A3CF2F08-07E3-469D-9244-A92D274A4118Q35800420-CB418669-68F6-4D38-ADD7-20C5B2264198Q35862393-AA02F578-66C0-4EC6-9EBC-F11AEFD71C8BQ36426832-E1D7AEE7-C82F-4146-BD53-BC6F5131FBBEQ36979367-26CEC463-6668-4160-862C-A97E49652002Q37158807-E4F5DA6D-50E9-496D-BC1F-11896F4D378BQ37321970-33FD07E1-D034-4FC6-AF71-227083369AD2Q37373486-E8510947-931D-4B87-949A-C5ECE98621A4Q37459395-A431F8C1-7291-4337-B2F0-C616D9C93D4CQ37586657-61D1536C-18F1-431E-962C-8D0C70C7B84FQ37973610-FCB3BE9E-3029-485C-8520-69B103BC9BAEQ38104109-2F1233F7-1384-47C3-BCBE-4AED42F7D955Q38108373-C6D45C1F-6D94-4200-B5BB-04F718A5F686Q39913767-EBBDCB31-016E-498F-A0DB-6C196600D72DQ41984177-2DC855EF-AE1E-4FDF-B2EB-0545CE10D55BQ43010488-CBA32ECC-BE3B-48EE-9FA0-DA9BB4D93BDEQ50598315-8FCC1382-8C6C-4852-946A-017A1A76943AQ50690444-9107704E-5AFB-453C-9896-AD6B447993A4Q57051319-BF45EF3C-9FB3-492F-8562-FB6B213FB6CA
P2860
Advanced glycation end products in nondiabetic patients with coronary artery disease.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Advanced glycation end products in nondiabetic patients with coronary artery disease.
@en
Advanced glycation end products in nondiabetic patients with coronary artery disease.
@nl
type
label
Advanced glycation end products in nondiabetic patients with coronary artery disease.
@en
Advanced glycation end products in nondiabetic patients with coronary artery disease.
@nl
prefLabel
Advanced glycation end products in nondiabetic patients with coronary artery disease.
@en
Advanced glycation end products in nondiabetic patients with coronary artery disease.
@nl
P2093
P1433
P1476
Advanced glycation end products in nondiabetic patients with coronary artery disease.
@en
P2093
Hashimoto T
Kanauchi M
Tsujimoto N
P304
P356
10.2337/DIACARE.24.9.1620
P407
P577
2001-09-01T00:00:00Z